IQV

IQVIA’s first quarter results were positively received by the market, reflecting stronger-than-expected revenue growth and solid execution in both its Commercial and R&D Solutions segments. Management attributed this outperformance to increased client demand across core offerings, particularly in areas integrating artificial intelligence and analytics. CEO Ari Bousbib highlighted that, “our organic revenue growth rate in Commercial Solutions doubled, and our organic revenue growth rate in R&D Solutions tripled,” compared to a year ago, with notable momentum in Patient Solutions and Analytics and Consulting. The company’s ability to secure large, multiyear contracts with leading pharmaceutical clients and to embed AI across business lines were key factors supporting robust top and bottom line performance. Is now the time to buy IQV? Find out in our full research report (it’s free). Revenue: $4.15 billion vs analyst estimates of $4.10 billion (8.4% year-on-year growth, 1.1% beat) Adjusted EPS: $2.90 vs analyst estimates of $2.82 (3% beat) Adjusted EBITDA: $932 million vs analyst estimates of $926.4 million (22.5% margin, 0.6% beat) The company reconfirmed its revenue guidance for the full year of $17.25 billion at the midpoint Management slightly raised its full-year Adjusted EPS guidance to $12.80 at the midpoint EBITDA guidance for the full year is $4 billion at the midpoint, in line with analyst expectations Operating Margin: 12.4%, in line with the same quarter last year Constant Currency Revenue rose 6% year on year (3.5% in the same quarter last year) Market Capitalization: $28.97 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Leerink Partners asked how the mix shift toward full-service bookings versus pass-throughs would affect future margins. CEO Ari Bousbib clarified that pass-throughs have no profit impact and that recent booking mix was a one-off event, not a new trend. Justin Bowers (Deutsche Bank) questioned if the change in booking mix signals a shift in client strategy or affects margin outlook. Bousbib reiterated that the mix was driven by specific trial types this quarter, not a broader shift...

Interested in IQVIA Holdings Inc.? Here are five stocks we like better. IQVIA posted record Q1 2026 results, with revenue of $4.151 billion and adjusted diluted EPS of $2.90, both above the high end of guidance. Management said growth accelerated in both Commercial Solutions and R&D Solutions. R&D demand and backlog remained strong, with net new bookings of $2.5 billion and backlog hitting a record $34.2 billion. Management said the clinical development pipeline and emerging biopharma activity continue to support future growth. The company is leaning heavily into AI, highlighting 192 deployed AI agents and the launch of IQVIA.ai, while saying AI is increasing client demand rather than reducing it. IQVIA also reaffirmed full-year revenue and EBITDA guidance and raised its adjusted EPS outlook. Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors IQVIA (NYSE:IQV) reported record first-quarter revenue and adjusted diluted earnings per share for 2026, with management citing accelerating organic growth across its Commercial Solutions and R&D Solutions businesses, increased demand tied to artificial intelligence offerings and continued strength in forward-looking clinical development metrics. Chairman and Chief Executive Officer Ari Bousbib said the company’s first-quarter revenue and adjusted diluted EPS exceeded the high end of guidance, reflecting “solid top and bottom-line performance.” He said organic revenue growth doubled year over year in Commercial Solutions and tripled in R&D Solutions. → Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum Total first-quarter revenue was $4.151 billion, up 8.4% on a reported basis and 6.0% at constant currency, Executive Vice President and Chief Financial Officer Mike Fedock said. Adjusted EBITDA rose 5.5% to $932 million. GAAP net income was $274 million, or $1.61 per diluted share, while adjusted net income was $492 million. Adjusted diluted EPS was $2.90, up 7.4% year over year. Commercial Solutions revenue was $1.754 billion in the quarter, up 11.6% on a reported basis and 8.5% at constant currency. Bousbib said organic growth in the segment was 5%, compared with about 2.5% in the prior-year period. → 3 Ways to Target the Resources Powering AI and Data Centers He attributed the improvement to continued product launches by clients, increased use of IQVIA services and strength in several areas, inc...

Clean Harbors, Inc. CLH reported mixed first-quarter 2026 results. Earnings per share (EPS) beat the Zacks Consensus Estimate, while revenues missed the same. The earnings beat failed to impress the market, as the stock has dipped 6.9% since the release of results on May 6. CLH posted first-quarter of 2026 earnings of $1.19 per share, beating the Zacks Consensus Estimate of $1.15 by 3.5%. Revenues came in at $1.46 billion, missing the consensus mark of $1.47 billion by 0.4%. Earnings grew 9.2% year over year, while revenues increased 1.9%. Management highlighted stronger profitability in both operating segments, supported by disciplined pricing and a late-quarter lift in base oil pricing, alongside a record-low Total Recordable Incident Rate (TRIR) of 0.39. Clean Harbors, Inc. price-consensus-eps-surprise-chart | Clean Harbors, Inc. Quote Clean Harbors described the quarter as better than expected, with higher profitability across both operating segments despite weather-related disruptions that weighed on parts of the collection and services business in February. Management also pointed to continued momentum exiting the quarter, framing the operating backdrop as supportive for its disposal and recycling network, with added tailwinds from project services and PFAS-related opportunities. Environmental Services generated first-quarter revenues of $1.24 billion, up 2.9% from the year-ago quarter. The company attributed growth to project services, including PFAS-related work and emergency response activity, while citing healthy demand for disposal and recycling services. Operationally, the company reported Technical Services revenue growth of 5% and Safety-Kleen Environmental Services revenue growth of 7%, aided by pricing and higher volumes. Incineration utilization, including the Kimball incinerator, was 80% versus 81% a year ago, reflecting planned maintenance days and weather impacts. Landfill volumes increased 34% and Field Services revenues rose 7%, including a large-scale emergency event that generated approximately $10 million in revenues. Safety-Kleen Sustainability Solutions posted revenues of $217.1 million, down 3.4% year over year, as lower market pricing for base and blended products outweighed other benefits. Management said that the revenue decline was expected, and noted that base oil prices strengthened late in the quarter. Even with the softer...

Republic Services, Inc. RSG delivered solid first-quarter 2026 results, with earnings per share of $1.70 beating the Zacks Consensus Estimate of $1.64 by 3.7%. Earnings increased 7.6% from $1.58 in the year-ago quarter. Revenues rose 2.6% year over year to $4.11 billion and edged past the consensus mark of $4.10 billion. Disciplined pricing and cost management supported profitability, as the adjusted EBITDA margin expanded 50 basis points to 32.1%. Republic Services, Inc. price-consensus-eps-surprise-chart | Republic Services, Inc. Quote Republic Services’ internal growth leaned heavily on price in the quarter. Core price on total revenues increased 5.7%, reflecting continued traction in open market pricing and restricted pricing, even as fuel recovery fees provided only a modest lift. Volume remained a headwind, with total revenues declining 0.8% on volume, while average yield added 3.4%. Management noted that severe weather weighed on activity during the quarter, but pointed to sequential improvement in several verticals, including landfill and container-related lines. Collection remained the largest contributor, generating $2.84 billion in revenues in the first quarter. Within the broader portfolio, small-container revenues rose to $1.31 billion, while large-container revenues came in at $768 million and residential revenues totaled $747 million, underscoring the scale of the core business. Transfer revenues (net) increased to $200 million and landfill revenues (net) rose to $453 million. Environmental solutions revenues (net) declined to $405 million, while “other” revenues increased to $217 million, led by recycling processing and commodity sales of $112 million alongside other non-core revenues. Profitability improved across the consolidated model, supported by cost-control and underlying operating leverage. Net income was $525 million, translating to a net income margin of 12.8%, up from 12.3% a year ago. On an adjusted basis, RSG reported $1.32 billion of adjusted EBITDA. By business type, Recycling & Waste produced adjusted EBITDA of $1.24 billion and an adjusted EBITDA margin of 33.6% compared with 33% in the prior-year quarter. Environmental Solutions generated adjusted EBITDA of $78 million with a margin of 19.2%, down from 20.8% last year, reflecting the year-over-year revenue decline in that business. RSG’s cash generation was a notable feature...

Shareholders of IQVIA Holdings Inc. (NYSE:IQV) will be pleased this week, given that the stock price is up 13% to US$179 following its latest quarterly results. Results were roughly in line with estimates, with revenues of US$4.2b and statutory earnings per share of US$1.61. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Taking into account the latest results, the consensus forecast from IQVIA Holdings' 20 analysts is for revenues of US$17.3b in 2026. This reflects a credible 3.9% improvement in revenue compared to the last 12 months. Statutory per-share earnings are expected to be US$8.23, roughly flat on the last 12 months. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$17.2b and earnings per share (EPS) of US$8.08 in 2026. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates. Check out our latest analysis for IQVIA Holdings There were no changes to revenue or earnings estimates or the price target of US$229, suggesting that the company has met expectations in its recent result. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values IQVIA Holdings at US$287 per share, while the most bearish prices it at US$195. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure. Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. The period to the end of 2026 brings more of the same, according to the analyst...

Corpay, Inc. CPAY is scheduled to release first-quarter 2026 results on May 7, after market close. The company surpassed the Zacks Consensus Estimate in the four trailing quarters, delivering an earnings surprise of 0.8%, on average. Corpay, Inc. price-eps-surprise | Corpay, Inc. Quote The Zacks Consensus Estimate for revenues is kept at $1.2 billion, hinting at a 20.1% jump from the year-ago quarter’s actual. For the Vehicle Payments segment, the Zacks Consensus Estimate for revenues is $558 million, suggesting a 14.6% year-over-year rally. We expect consistent growth of Vehicle Payments across the United States, Europe and Brazil to have aided revenues. The consensus mark for revenues from Corporate Payments is set at $488 million, suggesting an increase of 38.4% from the year-ago quarter’s actual. Solid improvement in Alpha performance and growth in spend volumes are likely to have benefited this segment. On the Lodging Payments front, the consensus estimate for revenues is pinned at $110 million, implying a marginal year-over-year dip. The Zacks Consensus Estimate for Other Payments revenues is set at $62 million, indicating 11.4% growth from the year-ago quarter’s actual. The consensus estimate for the bottom line is pegged at $5.5 per share, suggesting 11% year-over-year growth. Our model predicts an earnings beat for CPAY this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks before they are reported with our Earnings ESP Filter. Corpay has an Earnings ESP of +0.57% and a Zacks Rank of 3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here. TransUnion TRU delivered adjusted earnings of $1.18 per share in the first quarter of 2026, growing 12.4% year over year and beating the Zacks Consensus Estimate of $1.11 by 6.3%. Quarterly revenues were $1.25 billion, rising 13.7% from the year-ago period and topping the consensus mark of $1.21 billion by 3.1%. Organic constant-currency revenue growth was 10.7%, reflecting continued momentum across the key U.S. verticals. IQVIA Holdings Inc. IQV posted first-quarter 2026 adjusted earnings of $2.90 per share, beating the Zacks Consensus Estimate of $2.83 by 2.5%. Revenues came in at $4.15 billion, topping the consensus mark of $4.08 billion by 1.6%. The compan...

Organic revenue growth accelerated significantly, with Commercial Solutions doubling and R&D Solutions tripling its growth rate year over year. Commercial performance was bolstered by record pipeline levels and the highest growth in Analytics and Consulting in three years, driven by new drug launch activity. The company has transitioned to an 'AI-native' operating model, deploying 192 specialized agents across 64 use cases to drive operational efficiency and client insights. R&D Solutions growth was supported by faster-than-expected backlog conversion and solid net service fee bookings, despite a lower book-to-bill ratio caused by pass-through mix. Management attributes the strong demand environment to rising trial complexity and the need for clients to build AI-ready data foundations to modernize performance reporting. Strategic repositioning through a new segment reporting structure effective January 1, 2026, aims to better align offerings with clinical and commercial market dynamics. Full-year 2026 revenue guidance assumes approximately 150 basis points of contribution from acquisitions and 100 basis points of foreign exchange tailwinds. Management raised adjusted diluted EPS guidance for the full year, reflecting confidence in productivity programs and operational margin expansion. The $34.2 billion backlog includes $8.9 billion expected to convert to revenue within the next twelve months, representing nearly 8% growth over the prior year. EBP funding reached $25 billion in Q1, nearly double the prior year, which management views as a leading indicator for future clinical trial awards and backlog growth. Future R&D demand is expected to be fueled by large pharma using AI to identify more discovery-stage targets, necessitating increased CRO capacity for upcoming trials. The Q1 book-to-bill ratio of 1.04 was impacted by an unusually low mix of pass-through bookings, which were approximately one-third lower than the historic average. EBITDA margins saw a 60 basis point contraction in Q1 due to non-operational headwinds from FX and pass-throughs, though operational productivity remained strong. Management flagged that while the environment is stabilizing, large pharma sponsors remain more deliberate in capital deployment compared to pre-disruption speeds. A strategic regional promotion agreement with Pfizer covering 23 European countries highlights a shift t...

TransUnion TRU delivered adjusted earnings of $1.18 per share in the first quarter of 2026, growing 12.4% year over year and beating the Zacks Consensus Estimate of $1.11 by 6.3%. Quarterly revenues were $1.25 billion, rising 13.7% from the year-ago period and topping the consensus mark of $1.21 billion by 3.1%. Organic constant-currency revenue growth was 10.7%, reflecting continued momentum across the key U.S. verticals. TransUnion price-consensus-eps-surprise-chart | TransUnion Quote TransUnion’s U.S. Markets segment generated $975.1 million in revenues in the quarter, driven by Financial Services at $500.5 million. Emerging Verticals produced $334.7 million, while Consumer Interactive contributed $139.9 million. Management characterized the operating backdrop as relatively stable through mid-April, with customer demand and volume trends tracking at or ahead of expectations. The company highlighted commercial momentum in credit marketing and fraud solutions, alongside ongoing traction in non-credit offerings. TRU’s International segment posted $274 million in revenues, with results varying by geography. The U.K. delivered $72.2 million, while Latin America contributed $53.9 million and Canada produced $43.3 million. Africa revenues were $20.9 million. Offsetting those areas of strength, India revenues were $61.6 million and the Asia Pacific revenues were $22.1 million. Management noted that performance across India, Latin America and the Asia Pacific is expected to improve as 2026 progresses, supported by gradual recoveries and better comps in certain markets. TransUnion reported consolidated adjusted EBITDA of $437.9 million, up 10.3% year over year. The adjusted EBITDA margin was 35.2%, down from 36.2% in the prior-year quarter. On a GAAP basis, net income attributable to TransUnion increased to $397.1 million from $148.1 million a year ago, benefiting from a $225.5-million gain on the acquisition of an affiliate. Operating expenses rose year over year, with the cost of services at $519.5 million and selling, general and administrative expenses at $329.1 million. TRU emphasized that AI is driving growth in two ways: higher data use among certain customers and faster product innovation. Management pointed to new AI-enabled offerings built on OneTru, including an analytics workflow that uses Google’s Gemini models to streamline advanced credit modeling an...

For the quarter ended March 2026, IQVIA Holdings (IQV) reported revenue of $4.15 billion, up 8.4% over the same period last year. EPS came in at $2.90, compared to $2.70 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $4.08 billion, representing a surprise of +1.62%. The company delivered an EPS surprise of +2.66%, with the consensus EPS estimate being $2.83. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how IQVIA performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Commercial Solutions: $1.75 billion compared to the $1.71 billion average estimate based on two analysts. Revenues- Research & Development Solution: $2.4 billion versus $2.39 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +14% change. Segment profit- Commercial Solutions: $381 million versus $388.33 million estimated by two analysts on average. Segment Profit- Research & Development Solutions: $472 million versus $489.59 million estimated by two analysts on average. View all Key Company Metrics for IQVIA here>>> Shares of IQVIA have returned +3.4% over the past month versus the Zacks S&P 500 composite's +10.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report IQVIA Holdings Inc. (IQV) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

IQVIA Holdings Inc. IQV has posted first-quarter 2026 adjusted earnings of $2.90 per share, beating the Zacks Consensus Estimate of $2.83 by 2.5%. Revenues came in at $4.15 billion, topping the consensus mark of $4.08 billion by 1.6%. Results improved year over year, with adjusted diluted earnings per share up 7.4% and revenues rising 8.4%. The quarter benefited from better-than-expected organic growth across the business, supported by strengthening demand indicators, including a $34.2-billion contracted backlog in the Research & Development Solutions business. IQVIA Holdings Inc. price-consensus-eps-surprise-chart | IQVIA Holdings Inc. Quote Commercial Solutions delivered the sharpest top-line momentum in the quarter. Segmental revenues were $1.75 billion, increasing 11.6% on a reported basis and 8.5% at constant currency. Management highlighted notable strength across patient solutions, analytics and consulting, and commercial engagement services. The company also pointed to growing traction in AI-enabled offerings, suggesting product innovation is contributing to sales performance alongside broader market demand. Research & Development Solutions revenues were $2.40 billion, up 6.2% on a reported basis and 4.2% at constant currency. Excluding reimbursed expenses, R&D Solutions revenues increased 6.6% reported, reflecting healthier underlying service growth. Beyond reported revenues, the bookings picture remained constructive. Net new bookings were $2.5 billion, with a first-quarter book-to-bill ratio of 1.04X and a trailing-12-month ratio of 1.11X. The company also expects $8.9 billion of contracted work to convert into revenues over the next 12 months, indicating 7.6% year-over-year growth, offering a clearer line of sight into near-term demand. Profitability remained solid in the quarter, with adjusted EBITDA of $932 million, up 5.5% year over year. GAAP net income attributable to IQVIA was $274 million, reflecting continued earnings power alongside ongoing non-GAAP addbacks tied to restructuring and acquisition-related items. Cash generation was a key positive. The operating cash flow rose 9% year over year to $618 million, while the free cash flow increased 15% to $491 million. Notably, the free cash flow equaled 100% of adjusted net income, underscoring strong conversion and disciplined working-capital management. IQVIA reaffirmed its 2026 revenue gui...

IQVIA Holdings (IQV) came out with quarterly earnings of $2.9 per share, beating the Zacks Consensus Estimate of $2.83 per share. This compares to earnings of $2.7 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +2.66%. A quarter ago, it was expected that this clinical testing company would post earnings of $3.4 per share when it actually produced earnings of $3.42, delivering a surprise of +0.59%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. IQVIA, which belongs to the Zacks Medical - Instruments industry, posted revenues of $4.15 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 1.62%. This compares to year-ago revenues of $3.83 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. IQVIA shares have lost about 28.6% since the beginning of the year versus the S&P 500's gain of 5.2%. While IQVIA has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for IQVIA was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here...

Image source: The Motley Fool. Tuesday, May 5, 2026 at 9 a.m. ET Chairman and Chief Executive Officer — Ari Bousbib Executive Vice President and Chief Financial Officer — Michael Fedock Vice President, Investor Relations — Kerri Joseph Kerri Joseph: Thank you, operator. Good morning, everyone. Thank you for joining our first quarter 2026 earnings call. With me today are Ari Bousbib, Chairman and Chief Executive Officer; Michael Fedock, Executive Vice President and Chief Financial Officer; and members of our leadership and Investor Relations teams. Today, we will be referencing a presentation that will be visible during this call for those of you on our webcast. This presentation will also be available following this call in the Events and Presentations section of our IQVIA Holdings Inc. Investor Relations website at ir.iqvia.com. Before we begin, I would like to caution listeners that certain information discussed by management during this call will include forward-looking statements. Actual results could differ materially from those stated or implied by forward-looking statements due to risks and uncertainties associated with the company’s business, which are discussed in the company’s filings with the Securities and Exchange Commission, including our Annual Report on Form 10-Ks and subsequent SEC filings. In addition, we will discuss certain non-GAAP financial measures on this call which should be considered a supplement to and not a substitute for financial measures prepared in accordance with GAAP. A reconciliation of these non-GAAP measures to the comparable GAAP measures is included in the press release and conference call presentation. As previously disclosed, we implemented a new segment reporting structure effective 01/01/2026. In conjunction with this change, prior period segment amounts have been recast to conform to this new reporting structure. I would now like to turn the call over to our Chairman and CEO, Ari Bousbib. Ari Bousbib: Thank you, and good morning, everyone. Thank you for joining us today to discuss our first quarter results. IQVIA Holdings Inc. delivered outstanding financial results, achieving record first quarter revenue and adjusted diluted earnings per share that exceeded the high end of our guidance, reflecting solid top and bottom line performance. We are seeing continued positive year-over-year momentum across the portfolio...